A blueprint for a healthier tomorrow

We design and develop precision therapies, with the goal of transforming patient care. These include multiple programs for genomically defined cancers, rare diseases and cancer immunotherapy.

Our pipeline

Photo: R.S., living with systemic mastocytosis

Precision that moves

Our uniquely targeted, scalable approach empowers the rapid design and development of new precision therapies as we aim to stay one step ahead of disease.

Our platform

Make real the promise of precision medicine

We seek to deliver life-changing, enduring impact by combining precision with agility.

Our company

Photo: D.L., living with non-small cell lung cancer

Diversity sparks innovation

Our diverse team is passionate about science and thrives on working together to achieve the impossible. We use every opportunity to think differently, make bold decisions and pioneer novel solutions.

Our opportunities

Celebrating 10 years

We started with a clear mission: deliver transformative benefit to patients with medicines that target drivers of disease. A decade later, we are expanding our vision to make real the promise of precision therapy for as many people as possible.

View our post & video

Our commitment to patients

At Blueprint Medicines, we work together in pursuit of one common goal: to dramatically improve the lives of people with genomically defined diseases.

read on

Clinical programs

Kinome illustration reproduced courtesy of Cell Signaling Technology, Inc.

Avapritinib

development programs

  • Advanced gastrointestinal stromal tumors
  • Advanced systemic mastocytosis
  • Non-advanced systemic mastocytosis
Learn more

Kinome illustration reproduced courtesy of Cell Signaling Technology, Inc.

Kinome illustration reproduced courtesy of Cell Signaling Technology, Inc.

Pralsetinib

development programs

  • Advanced RET fusion-positive non-small cell lung cancer
  • Advanced RET-altered thyroid cancers
  • Other RET-altered solid tumors
Learn more

Kinome illustration reproduced courtesy of Cell Signaling Technology, Inc.

Kinome illustration reproduced courtesy of Cell Signaling Technology, Inc.

Fisogatinib

Development program

  • Advanced hepatocellular carcinoma
Learn more

Kinome illustration reproduced courtesy of Cell Signaling Technology, Inc.

Kinome illustration reproduced courtesy of Cell Signaling Technology, Inc.

Blu-263

development program

  • Non-advanced systemic mastocytosis
Learn more

Kinome illustration reproduced courtesy of Cell Signaling Technology, Inc.

Kinome illustration reproduced courtesy of Cell Signaling Technology, Inc.

Blu-782

development program

  • Fibrodysplasia ossificans progressiva
Learn more

BLU-782 is an investigational ALK2 inhibitor being developed for the treatment of FOP. In October 2019, we entered into an exclusive, worldwide license agreement with Clementia Pharmaceuticals, a subsidiary of Ipsen, to develop and commercialize BLU-782.

Kinome illustration reproduced courtesy of Cell Signaling Technology, Inc.

Meet the Blue Crew

Meet the Blue Crew

Rahul Kalathiya, Medical Science Liaison

My main responsibility is to build relationships with healthcare professionals, serving as a valuable resource and helping them make informed decisions for their patients. I provide education on our company’s treatments and current research efforts, including opportunities for investigator-initiated and company-sponsored trials. In addition, I gain insights on the real-world use of our therapies, current treatment landscape and future directions, and share these perspectives with our Medical Affairs organization so we can develop patient-centric strategies to address medical needs.

Read on
The Lens

We aspire to pioneer multiple new scientific advances in disease biology and the design of precision therapies. To learn more about our scientific leadership and perspectives, visit The Lens.

read on

Unleashing the vast potential of kinase therapies

Our presentations at ASCO

Seeking to deliver transformative medicines

Download Our latest corporate presentation
“We ignore traditional boundaries and let science drive us. It’s the only way to revolutionize how we treat cancer.”
Jeff Albers, Chief Executive Officer
“We ignore traditional boundaries and let science drive us. It’s the only way to revolutionize how we treat cancer.”
Jeff Albers, Chief Executive Officer

Dare to be different

We believe diversity is the key to unlocking our full potential. We push boundaries and take well-calculated risks, committing courageously and wholeheartedly to what we believe in.

read on